Injections and Portfolios - Esthetician Leadership Today

U.S. FDA Approves Celltrion’s STELARA Biosimilar

The Dermatology Digest

DECEMBER 18, 2024

Food and Drug Administration (FDA) has approved STEQEYMA (ustekinumab-stba), a biosimilar to STELARA (ustekinumab), for subcutaneous injection or intravenous infusion in adult and pediatric patients with plaque psoriasis and psoriatic arthritis, as well as adult patients with Crohn’s disease and ulcerative colitis. immunology market.”

Portfolios

Portfolios Injections Office Safety

Expanding Innovation and Education in Medical Aesthetics

Dermatology Times

OCTOBER 30, 2024

Bob Rhatigan, CEO of Merz Aesthetics, discusses the company’s commitment to advancing the aesthetics industry through strategic partnerships, specialized training, and a growing portfolio of injectables and devices.

Innovations

Innovations Portfolios Education Medical

FDA Approves JUVÉDERM VOLUMA XC for Filling Temple Hollows

The Dermatology Digest

MARCH 5, 2024

Food and Drug Administration has approved JUVÉDERM VOLUMA XC for injection in the temple region to improve moderate to severe temple hollowing in adults age 21 and older. The Allergan Medical Institute (AMI) team can train aesthetic providers on safe and effective treatments using the Allergan Aesthetics portfolio to address 90% of the face.

Portfolios

Portfolios Injections Training Facials

FDA Nod for PYZCHIVA (ustekinumab-ttwe), Samsung Bioepis’ Stelara Biosimilar

The Dermatology Digest

JULY 1, 2024

Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for PYZCHIVA (ustekinumab-ttwe) subcutaneous injection and intravenous infusion as a biosimilar to Stelara (ustekinumab). Samsung Bioepis has seven biosimilars approved in the US and four commercially available as of June 2024.

Portfolios

Portfolios Safety Clinic Injections

“From Novice to Expert: How Injectable Training Courses Can Elevate Your Skills.”

AAAMS

APRIL 18, 2024

Introduction to Injectable Training Courses Injectable training courses are your fastest ticket from being a beginner to a pro in the cosmetic industry. The journey starts with understanding what injectables are – substances like Botox and fillers that enhance facial features and diminish and promote a youthful appearance.

Injections

Injections Training Legal Safety

Sculptra – Will The New Mixing Method Cause More Nodules?

Skin Tour

MARCH 3, 2023

It gets mixed with sterile water and often lidocaine (numbing) prior to injecting it because it ships in a vial in powder form. Allergan bought this product and added it to its portfolio a few years ago. It should generate more sales by allowing newer providers and smaller clinics to inject Scultpra.

Injections

Injections Portfolios Sales Clinic

TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology in the U.S. and Abroad

The Dermatology Digest

SEPTEMBER 9, 2024

It incorporates Polyglutamic Acid (PGA), a peptide known for its hydrating properties The non-injectable Elastiderm Advanced Filler Concentrate is formulated with Acetyl Hexapeptide-1, to smooth wrinkles and add volume.

Portfolios

Portfolios Dermatology Injections Marketing

Incyte, CMS Partner to Develop Povorcitinib in Mainland China, Hong Kong, Macau, Taiwan, and Southeast Asia

The Dermatology Digest

APRIL 1, 2024

Huang Anjun, the general manager of CMS Skinhealth, adds, “We expect that this collaboration will enhance CMS Skinhealth’s portfolio of potential treatments for vitiligo that, if approved, will provide differentiated treatment options for vitiligo patients in China.

Portfolios

Portfolios Injections Innovations Sales

Topline Phase 1 Trial Results for Apogee’s APG777 in AD “Exceed Expectations”

The Dermatology Digest

MARCH 5, 2024

I am very encouraged by the initial data from this study, which demonstrate the potential for APG777 as a well-tolerated treatment with a half-life that would support less frequent injections.” Chief Executive Officer of Apogee, in a news release. Today’s announcement brings us an important step closer to achieving this goal.”

Injections

Injections Safety Sustainability Clinic

Cosmetic Corner: Botox Biosimilar Update, New Launches From Cynosure Lutronic and HydraFacial

The Dermatology Digest

OCTOBER 1, 2024

Food and Drug Administration (FDA) are aligned on the regulatory pathway for ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX (onabotulinumtoxinA) as the reference product. AEON Biopharma Receives Positive Outcome From FDA in Botox Biosimilar Meeting AEON Biopharma, Inc.

Hydration

Hydration Portfolios Office Surgery

Why Nurses Are Moving to Aesthetic Medicine

AAAMS

FEBRUARY 22, 2023

You’ll Experience Enhanced Job Security In the world of finance, a diversified investment portfolio is the key to mitigating risk and creating greater financial stability. Thanks to this foundation, RNs can learn to safely and skillfully perform Botox and dermal filler injections in a relatively short time.

Work-Life Balance

Work-Life Balance Training Office Marketing

10 Best Nasal Sprays for COVID-19 (2023)

Aesthetics Advisor

SEPTEMBER 15, 2023

For a full list of Marinomed’s portfolio of Carragelose® containing nasal sprays and oral products, please visit [link] , for a list of scientific publications on Carragelose®, [link]. Increasing clinical evidence indicates that Carragelose® can also inactivate SARS-CoV-2.[1],[2]

Hospital

Hospital Clinic Marketing Medical

Evolus Scores EU Approval of Estyme Injectable Hyaluronic Acid Gel Fillers Under New Medical Device Regulation Process

The Dermatology Digest

NOVEMBER 4, 2024

The EU Medical Device Regulation (MDR) certification gave its nod to four injectable hyaluronic acid (HA) gel fillers from Evolus under the brand name Estyme, The CE Mark certification, through the new MDR process, represents more stringent requirements, designed to ensure the safety, efficacy, and quality of medical devices sold in Europe.

Injections

Injections Medical Portfolios Branding

U.S. FDA Approves Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels

The Dermatology Digest

FEBRUARY 13, 2025

Food and Drug Administration (FDA) has approved EvolysseForm and EvolysseSmooth injectable hyaluronic acid (HA) gels, the first two products in Evolus, Inc. The commercial launch of these first two injectable HA gels in 2025 will be followed by EvolysseSculpt in 2026, and EvolysseLips in 2027. s Evolyssecollection. The post U.S.

Injections

Injections Portfolios Innovations Safety

Evolysse Officially Launches Evolysse Form and Evolysse Smooth

The Dermatology Digest

APRIL 16, 2025

Evolysse Form and Evolysse Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse collection, are officially launching on Friday, April 18, 2025. These products represent the next generation of injectable HA gels, scientifically driven, delivering natural-looking results, and backed by a strong safety profile.

Injections

Injections Portfolios Innovations Technology

Inside the Apogee Pipeline: Company Shares Updates on APG777 and APG990 for AD

The Dermatology Digest

DECEMBER 5, 2024

Apogee Therapeutics recently hosted its first R&D Day, which featured updates across its entire portfolio. APG777 and APG990 The combination of APG777 and APG990, an optimized anti-OX40L mAb has been shown to retain stability, injectability, and convenience of individual components.

Portfolios

Portfolios Dermatitis Sustainability Injections

U.S. FDA Approves Celltrion’s STELARA Biosimilar

Expanding Innovation and Education in Medical Aesthetics

FDA Approves JUVÉDERM VOLUMA XC for Filling Temple Hollows

FDA Nod for PYZCHIVA (ustekinumab-ttwe), Samsung Bioepis’ Stelara Biosimilar

“From Novice to Expert: How Injectable Training Courses Can Elevate Your Skills.”

Sculptra – Will The New Mixing Method Cause More Nodules?

TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology in the U.S. and Abroad

Incyte, CMS Partner to Develop Povorcitinib in Mainland China, Hong Kong, Macau, Taiwan, and Southeast Asia

Topline Phase 1 Trial Results for Apogee’s APG777 in AD “Exceed Expectations”

Cosmetic Corner: Botox Biosimilar Update, New Launches From Cynosure Lutronic and HydraFacial

Why Nurses Are Moving to Aesthetic Medicine

10 Best Nasal Sprays for COVID-19 (2023)

Evolus Scores EU Approval of Estyme Injectable Hyaluronic Acid Gel Fillers Under New Medical Device Regulation Process

U.S. FDA Approves Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels

Evolysse Officially Launches Evolysse Form and Evolysse Smooth

Inside the Apogee Pipeline: Company Shares Updates on APG777 and APG990 for AD

Stay Connected